Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy

Sponsor
Gangnam Severance Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05597683
Collaborator
(none)
50
1
2
23.9
2.1

Study Details

Study Description

Brief Summary

This study aims to assess whether transmusculr quadratus lomborum block (QL block) can reduce postoperative pain after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC). Patients will be randomly assigned to either QL block group or control group. Ultrasound-guided bilateral transmuscular quadratus lomborum block will be performed in QL block group using 0.375% ropivacaine. Multimodal analgesic regimen including acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), and rescue opioids will be used in every patient. Primary outcome is opioid consumption for 24 hours after surgery. Secondary outcomes included pain scores, time to first rescue analgesics, quality of recovery score, length of hospital stay.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
N/A

Detailed Description

Adult patients scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy will be screened for eligibility. After induction of general anesthesia, ultrasound-guided bilateral transmuscular quadratus lomborum block will be done in QL block group. 0.375% ropivacaine will be injected to each side. Patients in control group will receive no block. Multimodal analgesia will be applied to every patient for postoperative pain control. Multimodal analgesic regimen included scheduled administration of acetaminophen, NSAIDs, and rescue opioids. Blinded investigator will assess pain scores at rest and on movement at 6, 12, 24, 48, 72 hours after surgery, analgesic consumptions, nausea, vomiting, and quality of recovery questionnaire.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
hyperthermic intra-peritoneal chemotherapyhyperthermic intra-peritoneal chemotherapy
Masking:
Double (Participant, Care Provider)
Masking Description:
Patients, medical staff who measure outcome variables, and nurses in the recovery room are double-blinded so that medical staff and patients do not know the patient's assigned group.
Primary Purpose:
Treatment
Official Title:
Quadratus Lumborum Block for Analgesia After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (CRS and HIPEC): a Double-blind Randomized Controlled Trial
Actual Study Start Date :
Nov 15, 2022
Anticipated Primary Completion Date :
Oct 31, 2024
Anticipated Study Completion Date :
Nov 10, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: QL block group

Bilateral transmuscular QL block will be performed under ultrasound-guidance. Twenty mililiter of 0.375% ropivacaine will be injected to each side.

Procedure: Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including scheduled administration of acetaminophen, NSAIDs,nefopam, and rescue opioids Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including scheduled administration of acetaminophen, NSAIDs, nefopam, and rescue opioids

No Intervention: Control group

QL block will be not performed.

Outcome Measures

Primary Outcome Measures

  1. Total opioid consumption for 24 postoperative hours [24 hours postoperatively]

    Total opioid analgesic use for 24 hours after surgery (morphine milligram equivalents (MME))

Secondary Outcome Measures

  1. Analgesic consumption [at postoperative 6, 12, 48, 72 hours]

    Analgesic consumption at postoperative 6, 12, 48, 72 hours

  2. Resting pain numeric rating scale(NRS) [at postoperative 6, 12, 24, 48, 72 hours]

    Resting pain numeric rating scale(NRS) at postoperative 6, 12, 24, 48, 72 hours.

  3. Numeric rating scale of pain during movement [at postoperative 6, 12, 24, 48, 72 hours]

    Numeric rating scale of pain during movement at postoperative 6, 12, 24, 48, 72 hours

  4. Time to first rescue analgesics [within post-operative 24 hours]

    Time to first rescue analgesics

  5. Rescue analgesics administration [within post-operative 48 hours]

    Rescue analgesics administration count

  6. The incidence of post-operative nausea and vomiting [within post-operative 72 hours]

    The incidence of post-operative nausea and vomiting

  7. Patient satisfaction with pain control [At post-operative 72 hours]

    Patient satisfaction with pain control in 11 point scale (0-10), The higher the score, the higher the patient's satisfaction

  8. Quality of Recovery Questionnaire (15-item Quality of Recovery) [At post-operative 72 hours]

    Each item uses an 11-point numeric rating scale. The sum of the scores of the 15 items ranges from 0 to 150, with a high score indicating good quality of recovery.

  9. Pattern of injectate spread on ultrasonography [During quadratus lumborum (QL) block procedure]

    Pattern of injectate spread on ultrasonography

  10. Numeric rating scale at post anesthetic care unit (PACU) [30 minutes after the end of operation]

    Numeric rating scale at post anesthetic care unit. Numeric rating scare is 11-point scale from 0 to 10. The higher the number, the more severe the pain (0 is no pain at all, 10 is the most severe pain imaginable).

  11. Time to first ambulation [within post-operative 72 hours]

    Time to first ambulation

  12. Length of hospital stay [within postoperative 30 days]

    Length of hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patients who are scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC)
Exclusion Criteria:
  1. Allergy to local anesthetics or fentanyl

  2. Chronic pain

  3. Drug abuse

  4. Patients who are unable to use patient-controlled analgesia

  5. Skin infection at site for quadratus lomborum block

  6. pregnant or breatfeeding women

  7. Patients who are unable to communicate

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gangnam Severance Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Gangnam Severance Hospital

Investigators

  • Principal Investigator: Young Song, Gangnam Severance Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Young Song, Associate Professor, Gangnam Severance Hospital
ClinicalTrials.gov Identifier:
NCT05597683
Other Study ID Numbers:
  • 3-2022-0328
First Posted:
Oct 28, 2022
Last Update Posted:
Dec 6, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 6, 2022